Zentrale Empfehlungen und Statements der S3-Leitlinie zur komplementären Medizin für Patient*innen mit onkologischen Erkrankungen – Teil 1
Jutta Hübner(Goethe University Frankfurt), Jens Büntzel(Südharz Klinikum), Thorsten Schmidt(University of Tübingen), Oliver Micke(St. Franziskus Hospital), Karsten Münstedt(Justus-Liebig-Universität Gießen), F.J. Prott(Praxis für Humangenetik)
Cited by 2
Related Papers
Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis
|The Lancet Neurology|2004|1.1k
Transgenic rat model of Huntington's disease
|Human Molecular Genetics|2003|349
Inflammatory reactions and severe neutropenia in mice lacking the transcriptional repressor Gfi1
|Nature Genetics|2002|319
Nitric Oxide Destroys Zinc-Sulfur Clusters Inducing Zinc Release from Metallothionein and Inhibition of the Zinc Finger-Type Yeast Transcription Activator LAC9
|Biochemical and Biophysical Research Communications|1994|278
Knockdown of transactive response DNA‐binding protein (TDP‐43) downregulates histone deacetylase 6
|The EMBO Journal|2009|231